Mumbai-based medtech firm Bioscan Research has successfully secured US$1 million in a seed funding round led by Unicorn India Ventures. This capital infusion is earmarked to advance the company's mission of transforming early diagnosis for traumatic brain injuries. The funding will primarily support the market expansion and technological enhancement of its flagship device, CEREBO.
Addressing a Critical Gap in Emergency Care
Globally, an estimated 69 million people suffer from traumatic brain injuries each year, with a staggering 50 to 90 percent of mild cases going undiagnosed. These undetected injuries can lead to severe long-term complications, making rapid and accurate diagnosis within the critical "golden hour" essential. Bioscan Research aims to fill this significant gap in emergency medical services with its innovative technology.
Innovative Technology for Rapid Diagnosis
The company's core product, CEREBO, is a portable, non-invasive device that utilizes near-infrared spectroscopy and machine learning to detect intracranial bleeding. This radiation-free technology allows first responders and clinicians to perform a quick, one-minute scan at the point of care, such as on roadsides or in rural clinics. This capability dramatically changes the timeline for making critical treatment decisions for trauma patients.
Founded in 2017 by Shilpa Malik, a former defense R&D scientist, and Anupam Lavania, a deep-tech product expert, Bioscan Research is an ISO-certified medical device company. The firm's approach integrates advanced photonics, precision engineering, and artificial intelligence to create solutions that improve diagnostic accuracy. This multidisciplinary expertise underpins the development of CEREBO and its potential to enhance patient care significantly.
Strategic Allocation of New Capital
With the new capital, Bioscan Research will focus on a strategic plan for growth and product development. A significant portion of the funds will be directed toward accelerating market expansion across India and into international territories. The company also intends to upgrade its existing technology and strengthen its portfolio of intellectual property.
Securing additional regulatory approvals is another key objective that this funding will support, enabling entry into new global markets. The founders stated that the investment will help overcome the limitations of traditional diagnostic tools and improve access to timely emergency care. This strategic allocation is designed to scale the company's impact on a global level.
Investor Confidence and Market Potential
Anil Joshi, Managing Partner at lead investor Unicorn India Ventures, expressed strong confidence in the medtech startup's potential. He highlighted the persistent gaps in the healthcare industry and the immense market for solutions addressing head injuries and brain trauma. Joshi noted that Bioscan Research is making non-invasive detection of intracranial hemorrhage a reality and has shown impressive progress.
The company's recent performance, including a reported five-fold growth over the last 12 months, further validates this investor confidence. Bioscan Research is now targeting a three-fold growth trajectory in the upcoming year, driven by its planned expansion. This momentum positions the company to capitalize effectively on the growing demand for rapid brain injury diagnostics.
This US$1 million seed funding marks a pivotal moment for Bioscan Research, empowering the company to scale its operations and refine its life-saving diagnostic technology. The investment not only validates its innovative approach but also accelerates its mission to improve outcomes for brain injury patients worldwide. As CEREBO becomes more widely available, it holds the promise of transforming emergency response and saving countless lives.